In 188 HIV-infected children receiving efavirenz, a lower mid-dose (C12) was associated with a higher risk of HIV-1 viral load >400 copies/mL (P = 0.03). Simulations for a normalized population receiving US Food and Drug Administration weight-band dosing predicted that 15% of children would have a C12 below target threshold (<1.0 mg/L) with a 23% risk of viral replication.
Supplemental Digital Content is available in the text.
From the *Institut de recherche pour le développement (IRD UMI 174-PHPT), Marseille, France; †Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; ‡Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; §Ecole Doctorale de Santé Publique, Université Paris Saclay, Paris, France; ¶Harvard School of Public Health, Boston, Massachusetts; ‖Unité de Recherche Clinique Paris Centre, Assistance Publique Hôpitaux de Paris; **CIC1419, INSERM & APHP, EAU08 Université Paris Descartes Sorbonne Paris Cité, Paris, France; ††Chiangrai Prachanukroh Hospital, Chiangrai, Thailand; ‡‡Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; §§Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ¶¶Samutsakhon Hospital, Samutsakhon, Thailand; and ‖‖Somdej Prapinklao Hospital, Bangkok, Thailand.
Accepted for publication March 12, 2015.
S. Urien and G. Jourdain contributed equally to this study.
N. Homkham received a scholarship from IRD, France. The authors have no other funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Gonzague Jourdain, MD, PhD, Institut de recherche pour le développement (IRD), UMI 174-PHPT, 187/10, Changklan Road, Changklan, Muang, Chiang Mai 50100, Thailand. E-mail: email@example.com.